



In hypertension,

Tazloc

Telmisartan 20/40/80 mg Tablets

In patients with T2DM, Dyslipidemia, ASCVD & ACS,

Roseday[®]

Rosuvastatin 5/10/20/40 mg

In patients with ACS & CCS,

Ecosprin[®] **GOLD**

Gastro-resistant Aspirin 75 mg + Clopidogrel 75 mg + Atorvastatin 10/20 mg

JOURNAL OF THE INDIAN MEDICAL ASSOCIATION :

Sir Nilratan Sircar IMA House, 53, Sir Nilratan Sarkar Sarani (Creek Row), Kolkata - 700 014

Phone : (033) 2237- 8092, Mobile : +919477493027; E-mail : jima1930@rediffmail.com

Website : <https://onlinejima.com> ; www.ima-india.org/ejima

Head office : Indian Medical Association, IMA House, Indraprastha Marg, New Delhi - 110 002

Telephones : +91-11-2337 0009, 2337 8680, Email : hsg@ima-india.org ; Website : www.ima-india.org

Registration No. KOL RMS / 476 / 2020 - 2022

RNI Regd. No. 2557/1957

Vol. 64, No, 09, September 2020, Kolkata

Date of Publication : 15th September 2020

For the treatment of mild to moderate COVID-19*

Covihalt®
Favipiravir 200mg Tabs

Halt Fear Restore Health

- Faster viral clearance time¹
- Improved clinical recovery rate²
- Controls disease progression of COVID-19¹

At ₹49 Per Tablet Only

6 months Shelf life

***For restricted emergency use**
1. Cai Q, Yang M, Liu D, Chen J, Shi D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C. Experimental treatment with favipiravir for COVID-19: an open-label control study. *Engineering*. 2020 Mar 18.
2. Chen C, Huang J, Cheng Z, Wu J, Chen G, Zhang Y, Chen B, Lu M, Luo Y, Zhang J, Yin P. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. *MedRxiv*. 2020 Jan 1.

Abbreviated Prescribing Information (AbPI)
Active Ingredient: Favipiravir 200 mg. **Indication:** For the treatment of adults in mild to moderate COVID-19 disease under restricted emergency use. **Dosage and Administration:** The recommended dosage of favipiravir for adults is 1800 mg orally twice daily on 1st day followed by 800 mg orally twice daily, up to maximum of 14 days. **Contraindications:** Women known or suspected to be pregnant (Early embryonic deaths and teratogenicity have been observed in animal studies), lactating women, severe renal and hepatic impairment. **Hypersensitivity** to the active substances or to any of the excipients. **Warnings:** When administering favipiravir to women of child-bearing potential, confirm a negative pregnancy test result before starting the treatment. Explain fully the risks and instruct thoroughly to use most effective contraceptive methods with her partner during and for 7 days after the end of the treatment. If pregnancy is suspected during the treatment, instruct to discontinue the treatment immediately and to consult a doctor. Favipiravir is distributed in sperm. When administering the drug to male patients, explain fully the risks and instruct thoroughly to use most effective contraceptive methods in sexual intercourse during and for 7 days after the end of the treatment (men must wear a condom). In addition, instruct not to have sexual intercourse with pregnant women. Prior to the treatment, explain thoroughly the efficacy and risks (including the risk of exposure to fetus) to patients or their family members and written informed consent from each patient/ or his representative prior to administration of the drug shall be obtained by the prescriber. **Precautions:** Caution in patients with history of abnormalities in metabolism of uric acid or having Gout. Psychoneurotic symptoms such as abnormal behavior after administration of anti-influenza virus agents including favipiravir have been reported. **Drug Interactions:** Favipiravir mostly metabolized by aldehyde oxidase (AO), and partly metabolized by xanthine oxidase (XO). The drug inhibits AO and CYP2C8, but does not induce CYP. **Precautions for co-administration of Pyrazinamide, Repaglinide, Farnesylthio, Sulindac.** **Pregnancy & Lactation:** Contraindicated in pregnant and lactating women. **Adverse Events:** The major undesirable effects observed in clinical studies with favipiravir used at different doses included: increase of blood uric acid level, diarrhoea, decrease of neutrophil count, increase of AST (SGOT), increase of ALT (SGPT), psychiatric symptoms. The following clinically significant adverse reactions have been reported with other anti-influenza virus agents. Patients should be carefully monitored, and if any abnormality is observed, the treatment should be discontinued and appropriate measures should be taken: Shock, anaphylaxis, Pneumonia, Hepatic fulminant, Hepatic dysfunction, Jaundice, Toxic epidermal necrolysis (TEN), Oculo-muco-cutaneous syndrome (Stevens-Johnson syndrome), Acute renal failure, White blood cell count decreased, Neutrophil count decreased, Platelet count decreased. **Written informed consent from each patient/ or his representative prior to administration of the drug shall be obtained by the prescriber i.e. medical specialist.**
For the use only of registered medical practitioners or a hospital or a laboratory.

If not delivered please return to
Journal of the IMA (JIMA)
53, Sir Nilratan Sarkar Sarani,
(Creek Row), Kolkata - 700014

Printed and Published by **Dr Sanjoy Banerjee** on behalf of Indian Medical Association and printed at Prabaha, 45,
Raja Rammohan Sarani, Kolkata - 700009 and Published from Sir Nilratan Sircar IMA House, 53, Sir Nilratan
Sarkar Sarani (Creek Row), Kolkata 700014, Editor : **Dr Jyotirmoy Pal**